Jawan W. Abdulrahim

Jawan W. Abdulrahim

Auto-generated profile, based on publicly available information

Jawan W. Abdulrahim

Division of Cardiology, Department of Medicine, Duke University School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JRJessica A. Regan
Jessica A. Regan
JAJawan W. Abdulrahim
Jawan W. Abdulrahim
NBNathan A. Bihlmeyer
Nathan A. Bihlmeyer
CHCarol Haynes
Carol Haynes
LKLydia Coulter Kwee
Lydia Coulter Kwee
SSSvati H. Shah
Svati H. Shah

1 October 2022 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
NNNavid A. Nafissi
Navid A. Nafissi
JAJawan W. Abdulrahim
Jawan W. Abdulrahim
LKLydia Coulter Kwee
Lydia Coulter Kwee
ACAmanda C. Coniglio
Amanda C. Coniglio
WKWilliam E. Kraus
William E. Kraus
SSSvati H. Shah
Svati H. Shah
Background: Inherited primary arrhythmia syndromes and arrhythmogenic cardiomyopathies can lead to sudden cardiac arrest in otherwise healthy individuals. The burden and expression of these diseases in a real-world, well-phenotyped cardiovascular population is not well understood. Methods: Whole exome sequencing was performed on 8574 individuals from the CATHGEN cohort (Catheterization Genetics). Variants in 55 arrhythmia-related genes (associated with 8 disorders) were identified and assessed for pathogenicity based on American College of Genetics and Genomics/Association for Molecular Pathology criteria. Individuals carrying pathogenic/likely pathogenic (P/LP) variants were grouped by arrhythmogenic disorder and matched 1:5 to noncarrier controls based on age, sex, and genetic ancestry. Long-term phenotypic data were annotated through deep electronic health record review. Results: Fifty-eight P/LP variants were found in 79 individuals in 12 genes associated with 5 arrhythmogenic disorders (arrhythmogenic right ventricular cardiomyopathy, Brugada syndrome, hypertrophic cardiomyopathy, LMNA -related cardiomyopathy, and long QT syndrome). The penetrance of these P/LP variants in this cardiovascular cohort was 33%, 0%, 28%, 83%, and 4%, respectively. Carriers of P/LP variants associated with arrhythmogenic disorders showed significant differences in ECG, imaging, and clinical phenotypes compared with noncarriers, but displayed no difference in survival. Carriers of novel truncating variants in FLNC, MYBPC3 , and MYH7 also developed relevant arrhythmogenic cardiomyopathy phenotypes. Conclusions: In a real-world cardiovascular cohort, P/LP variants in arrhythmia-related genes were relatively common (1:108 prevalence) and most penetrant in LMNA . While hypertrophic cardiomyopathy P/LP variant carriers showed significant differences in clinical outcomes compared with noncarriers, carriers of P/LP variants associated with other arrhythmogenic disorders displayed only ECG differences.

1 December 2024 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
MRMegan E. Ramaker
Megan E. Ramaker
JAJawan W. Abdulrahim
Jawan W. Abdulrahim
KCKristin M. Corey
Kristin M. Corey
RRRyne C. Ramaker
Ryne C. Ramaker
LKLydia Coulter Kwee
Lydia Coulter Kwee
SSSvati H. Shah
Svati H. Shah
BACKGROUND: Interpretation of variants of uncertain significance (VUSs) remains a challenge in the care of patients with inherited cardiovascular diseases (CVDs); 56% of variants within CVD risk genes are VUS, and machine learning algorithms trained upon large data resources can stratify VUS into higher versus lower probability of contributing to a CVD phenotype. METHODS: We used ClinVar pathogenic/likely pathogenic and benign/likely benign variants from 47 CVD genes to build a predictive model of variant pathogenicity utilizing measures of evolutionary constraint, deleteriousness, splicogenicity, local pathogenicity, cardiac-specific expression, and population allele frequency. Performance was validated using variants for which the ClinVar pathogenicity assignment changed. Functional validation was assessed using prior studies in >900 identified VUS. The model utility was demonstrated using the Catheterization Genetics (CATHGEN) cohort. RESULTS: We identified a top-ranked model that accurately prioritized variants for which ClinVar clinical significance had changed (n=663; precision-recall area under the curve, 0.97) and performed well compared with conventional in silico methods. This model (CVD pathogenicity predictor [CVD-PP]) also had high accuracy in prioritizing VUS with functional effects in vivo (precision-recall area under the curve, 0.58). In CATHGEN, there was a greater burden of higher CVD-PP scored VUS in individuals with dilated cardiomyopathy compared with controls ( P =8.2×10 − 15 ). Of individuals in CATHGEN who harbored highly ranked CVD pathogenicity predictor VUS meeting clinical pathogenicity criteria, 27.6% had clinical evidence of disease. Variant prioritization using this model increased genetic diagnosis in CATHGEN participants with a known clinical diagnosis of hypertrophic cardiomyopathy (7.8%–27.2%). CONCLUSIONS: We present a cardiac-specific model for prioritizing variants underlying CVD syndromes with high performance in discriminating the pathogenicity of VUS in CVD genes. Variant review and phenotyping of individuals carrying VUS of pathogenic interest support the clinical utility of this model. This model could also have utility in filtering variants as part of large-scale genomic sequencing studies.

11 December 2021 in medRxiv
Verified
Preprint
Open access
PDF file
JRJessica A. Regan
Jessica A. Regan
JAJawan Abdulrahim
Jawan Abdulrahim
NBNathan Bihlmeyer
Nathan Bihlmeyer
CHCarol Haynes
Carol Haynes
LKLydia Coulter Kwee
Lydia Coulter Kwee
SSSvati H. Shah
Svati H. Shah
Background: Genetic loci associated with risk of severe COVID-19 infection have been identified and individuals with complicated COVID-19 infections often have multiple comorbidities. Objective: Identify known and unidentified comorbidities associated with genetic loci linked to risk of severe COVID-19 infection. Methods: A Phenome Wide Association Study (PheWAS) was conducted in 247,448 unrelated, white individuals from the UK Biobank to test the association of 1,402 unique phenotypes with ten genome-wide significant severe-COVID risk single nucleotide polymorphisms (SNP) identified from prior studies. A validation PheWAS was conducted in 2,247 white individuals from the CATHGEN. Results: Four of the ten tested genetic loci showed significant phenotypic associations in UK Biobank after FDR adjustment. Vascular dementia significantly associated with rs7271165 near TMEM65 on 8q24.13 in individuals with the C risk allele (OR 5.66 [95% CI 2.21-11.85], q=0.049). We identified 40 novel phenotype associations with rs657152 on 9q34.2 coinciding with the ABO gene with individuals with the A COVID risk allele having higher odds of heart failure (OR 1.09 [95% CI 1.03-1.14], q=0.004), diabetes mellitus (OR 1.05 [95% CI 1.02-1.07], q=0.004) and hypercholesterolemia (OR 1.04 [95% CI 1.02-1.06], q=6.3×10 −5 ). Eight phenotypes associated with rs1819040 near KANSL1 on 17q21.31 in individuals with the A risk allele including atrial fibrillation and flutter (OR 1.07 [95% CI 1.04-1.10], q=0.0084) and pulmonary fibrosis (OR 0.80 [95% CI 0.71-0.89], q=0.035). Ten novel phenotypic associations were identified in association with rs74956615 on 19p13.2 near the TYK2 gene including individuals with the A COVID risk allele having lower odds of psoriatic arthropathy (OR 0.31 [95% CI 0.20-0.47], q=4.5×10 −5 ), rheumatoid arthritis (OR 0.83 [95% CI 0.64-0.83], p=1.4×10 −6 ) and thyrotoxicosis with or without goiter (OR 0.77 [95% CI 0.68-0.87], p-6.9×10 −5 ). Two associations for rs1819040 ( KANSL1 ) and seven associations for rs74956615 ( TYK2 ) validated in CATHGEN. Conclusions: Using a broad PheWAS approach in a large discovery and validation cohort, we have identified novel phenotypic associations with risk alleles for severe COVID-19 infection. Interestingly, the ABO locus was associated with comorbidities that are also risk factors for severe COVID-19 infection, suggesting that this locus has pleiotropic effects and provides a potential mechanism for this association. The 19p13 locus was associated with lower risk of autoimmune disease, these findings may have broad implications for the importance of multiple comorbidities across both infectious and non-infectious diseases and may provide insight in the molecular function of the genes near these genetic risk loci.

14 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MRMegan E. Ramaker
Megan E. Ramaker
KCKristin M. Corey
Kristin M. Corey
JRJessica A. Regan
Jessica A. Regan
SCSara Coles
Sara Coles
JAJawan W. Abdulrahim
Jawan W. Abdulrahim
SSSvati H. Shah
Svati H. Shah
Background Monogenic cardiovascular diseases (MCVD) remain substantially under-diagnosed, and thus interest is shifting from a phenotype-forward approach towards a genotype-first strategy that applies to population-wide genomic screening. We evaluated the prevalence of pathogenic and predicted pathogenic MCVD variants and assessed disease expression in the population-based UK Biobank (UKB) cohort to determine whether yield is greater in phenotype-versus genotype-forward approach. Methods Pathogenic and likely pathogenic (P/LP) variants, and variants of uncertain significance (VUS) predicted to be pathogenic (pp-VUS) in 47 MCVD genes were assessed. In the genotype-forward approach, UKB participants with P/LPs or pp-VUS were assessed for symptoms of disease using electronic health record (EHR) interrogation, emulating a clinical approach to population-based screening. In the phenotype-forward approach, participants with stricter EHR-based evidence of disease expression were identified (emulating current clinical care) and the presence of P/LPs and pp-VUS was determined. Results Following QC, 467,850 participants were included. Overall, 1 in 125 participants in UKB carry an MCVD P/LP. In the genotype-forward approach, 3,709 (0.79%) participants carried an MCVD P/LP and 42.1% of these had symptoms of the associated MCVD; another 29,269 (6.3%) carried a pp-VUS with 21.5% of these having symptoms of disease. In the phenotype-forward approach, 62,488 (13.4%) expressed an MCVD using strict evidence of disease expression and of these individuals 1% carried an associated P/LP variant and 2.4% carried an associated pp-VUS. Conclusion We show here that a genotype-forward approach leads to a 2.5 times higher diagnostic yield (3.6 times higher when considering pp-VUS) compared with the phenotype-forward approach, which missed 936 P/LP carriers with disease symptoms. While cost, access and ethics need to be considered, these results support expanded population-based genetic screening to improve diagnosis of potentially treatable MCVD.